Strategic partnerships Leverage VERAXA’s active collaborations, including OmniAb and Secarna partnerships, to position potential co-development or licensing opportunities in antibody-drug conjugates, BiTAC TCEs, and antibody oligonucleotide conjugates with your own client portfolio.

Clinical pipeline Target oncology-focused pharmaceutical companies seeking next-gen ADCs and TCEs. VERAXA’s BiTAC platform and tumor-specific activity offer a value proposition for partners aiming to improve therapeutic windows and reduce off-tumor toxicity.

Financial momentum Note the company’s NASDAQ listing and recent leadership appointment, signaling maturation and growing financial credibility. This creates opportunities for early-stage collaborations or strategic investments with potential for scalable joint programs.

Expansion potential With a global biotech footprint, ongoing collaborations, and expansion into antibody oligonucleotide conjugates, there is room to propose multi-modal collaborations across oncology, autoimmune, and chronic conditions leveraging VERAXA’s conjugation tech.

Evidence of efficacy Preclinical results showing selective targeting of cancer cells with dual-biomarker recognition can be a strong talking point to engage risk-adjusted partnerships and co-development deals with firms seeking differentiated therapeutic profiles.